AZ, Chi-Med test savolitinib in kidney cancer
AstraZeneca and Hutchison China MediTech (Chi-Med) have begun trialling savolitinib in patients with a particular type of kidney cancer in a global, open-label, randomised Phase III registration study
Read More
